FLORONE E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLORONE E (FLORONE E).
FLORONE E contains diflorasone diacetate, a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and reducing prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Metabolized primarily in the liver via reduction, oxidation, and conjugation; hepatic enzyme pathways are involved but specific CYP isoenzymes are not well-defined. |
| Excretion | Primarily renal (<1% unchanged as metabolite) and biliary, with <1% excreted unchanged in urine. The remainder is metabolized and excreted in feces via bile. |
| Half-life | Approximately 2-4 hours (terminal) for the active moiety diflorasone; clinically, this supports twice-daily dosing for chronic skin conditions. |
| Protein binding | Extensive binding to plasma proteins, primarily albumin, with >90% bound. |
| Volume of Distribution | Not well characterized in humans; estimated to be 0.5-1.0 L/kg, suggesting distribution into total body water. |
| Bioavailability | Topical: variable, approximately 1-5% systemically absorbed through intact skin; increased 10-100% with occlusion, inflammation, or damaged skin. |
| Onset of Action | Topical application: noticeable improvement within 1-2 weeks; occlusive dressing may hasten onset to days. |
| Duration of Action | Clinical effect lasts 12-24 hours after topical application, with twice-daily dosing required; prolonged use may lead to tachyphylaxis. |
Apply a thin film to affected skin area twice daily. Not for ophthalmic, oral, or intravaginal use.
| Dosage form | CREAM |
| Renal impairment | No specific renal adjustment required; systemic absorption minimal with topical use. |
| Liver impairment | No specific hepatic adjustment required; systemic absorption minimal with topical use. |
| Pediatric use | Apply a thin film to affected area twice daily; limit treatment duration and avoid occlusive dressings due to increased systemic absorption. Safety not established in children <2 years. |
| Geriatric use | Apply a thin film to affected area twice daily; use caution due to thinner skin and increased potential for systemic absorption. Limit potency and duration of therapy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FLORONE E (FLORONE E).
| Breastfeeding | Systemic corticosteroids appear in breast milk. Topical administration of Florone E has unknown transfer. M/P ratio: not established. Caution: avoid application to breast area to prevent infant ingestion. Use only if clearly needed. |
| Teratogenic Risk | Florone E (diflorasone diacetate) is a corticosteroid. Topical administration results in minimal systemic absorption. Animal studies have shown corticosteroids to be teratogenic (cleft palate) after systemic exposure. No adequate human studies. Risk cannot be excluded. Use only if potential benefit justifies risk. Fetal risk cannot be ruled out (Category C). First trimester: theoretical risk, avoid large areas or occlusive dressings. Second/third trimester: use lowest effective dose, shortest duration. |
■ FDA Black Box Warning
Topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria, especially with prolonged use, large surface areas, occlusion, or pediatric use.
| Serious Effects |
Hypersensitivity to diflorasone diacetate or any component of the formulation; untreated bacterial, viral, or fungal infections at the application site.
| Precautions | Systemic absorption may produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. Use with caution in pediatric patients due to higher skin surface-to-body-weight ratio. Avoid prolonged use, occlusive dressings, and application to large areas. Monitor for local adverse reactions including atrophy, striae, and secondary infection. Not for ophthalmic use. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of adrenal suppression in mother and neonate if prolonged or extensive use. Monitor fetal growth by ultrasound if chronic high-dose use. Monitor maternal blood pressure and glucose due to potential systemic effects. |
| Fertility Effects | No specific human data on fertility effects. Animal studies with corticosteroids have shown impaired fertility at high systemic doses. Topical use is unlikely to impact fertility due to low systemic absorption. |